FOLH1 and metastatic malignant neoplasm in the lymph nodes: Meanwhile, there is some evidence that lymph node metastasis responds better to 177Lu-PSMA therapy than bone metastasis, which is attributed to the higher and more uniform radiation dose absorbed by lymph node metastasis [48].